Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Lignende værker

• Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
  af: Kuhn, Deborah J., et al.
  Udgivet: (2009)
• Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib
  af: Panagiotis Efentakis, et al.
  Udgivet: (2020-07-01)
• Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib
  af: Efentakis, Panagiotis, et al.
  Udgivet: (2020)
• Therapeutic Landscape of Carfilzomib and Other Modulators of the Ubiquitin-Proteasome Pathway
  af: Mitsiades, Constantine S.
  Udgivet: (2015)
• Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma
  af: Perel, Galina, et al.
  Udgivet: (2016)